Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure

Lutz, Thomas

doi:10.1038/ijosup.2016.4

Cited by 11 publications

(11 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, GLP-1 is an anorexigenic incretin produced by the intestinal L-cells that stimulates insulin secretion while also inducing satiety. 28 The results shown in Table 3 indicated that the group taking the polyphenolic dietary supplement presented higher levels of this cytokine after two months compared to the placebo group, most likely contributing to the satiety effect perceived by the consumers (Fig. 2).…”

Section: Discussion Of Resultsmentioning

confidence: 95%

Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

Based on previous evidence we postulate that AMP-activated protein kinase may have a role in such effects through its capability to modulate energy homeostasis, total daily energy expenditure and lipid management. Although further research may be required, we propose that this polyphenolic combination may be used for weight management by increasing long-term weight loss maintenance through the modulation of appetite biomarkers. This may help to avoid the undesired weight regain typical of calorie restriction diets.

show abstract

Section: Discussion Of Resultsmentioning

confidence: 95%

Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In an attempt to identify nuclei within the brain that may offer a complementary set of neural circuits that mediate, at least in part, the combined anorectic effects of amylin and GLP-1 pharmacotherapy, we focused our attention on those nuclei in the DVC given the wealth of literature showing the contribution of this structure to the intake suppressive effects of either amylin- or GLP-1-based monotherapy 6–8,10 . Specifically, we performed c-Fos fluorescent immunohistochemistry on brainstem coronal sections containing the DVC following acute treatment with sCT (3 μg/kg; IP ), liraglutide (50 μg/kg; IP ), sCT + liraglutide or vehicle (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…While the appetite suppressive effects of amylin and GLP-1 receptor agonists are known to involve direct actions in the brain 6,7,9,10,12–14 , uncovering the neuroanatomical site(s) of action and the physiological mechanisms that mediate the anorectic response remains an area of intense research focus. In the hindbrain, the dorsal-vagal-complex (DVC), collectively comprised of the nucleus tractus solitarius (NTS), area postrema (AP) and dorsal motor nucleus of the vagus (DMV), mediates the anorectic effects of both amylin and GLP-1 receptor agonists 15–19 .…”

Section: Introductionmentioning

confidence: 99%

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

Liberini

Koch‐Laskowski

Shaulson

et al. 2019

Sci Rep

View full text Add to dashboard Cite

A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has highlighted combination therapies as a promising strategy to enhance sustained weight loss. Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therapies produce greater food intake- and body weight-suppressive effects compared to monotherapies in both lean and diet-induced obese (DIO) rats. In chow-maintained rats, systemic amylin and GLP-1 combine to reduce meal size. Furthermore, the amylin and GLP-1 analogs salmon calcitonin (sCT) and liraglutide produce synergistic-like reductions in 24 hours energy intake and body weight. The administration of sCT with liraglutide also led to a significant enhancement in cFos-activation in the dorsal-vagal-complex (DVC) compared to mono-therapy, suggesting an activation of distinct, yet overlapping neural substrates in this critical energy balance hub. In DIO animals, long-term daily administration of this combination therapy, specifically in a stepwise manner, results in reduced energy intake and greater body weight loss over time when compared to chronic mono- and combined-treated groups, without affecting GLP-1 receptor, preproglucagon or amylin-receptor gene expression in the DVC.

show abstract

“…Apart from its participation in glycemic control, liraglutide acts centrally to lower food intake and increase energy expenditure (16,86). Central injection of liraglutide promotes weight loss via suppressing appetite and increasing energy dissipation, the latter is associated with enhanced lipolysis in WAT and thermogenesis in BAT (87,88). Particularly, administrating liraglutide into the ARH, PVH or LH decreases food intake and body weight, but does not alter UCP1 expression in BAT and WAT.…”

Section: Glucagon-like Peptide-1 (Glp-1)mentioning

confidence: 99%

AMPK in the Ventromedial Nucleus of the Hypothalamus: A Key Regulator for Thermogenesis

Liu

2020

Front. Endocrinol.

View full text Add to dashboard Cite

Obesity has become a global health issue, but effective therapies remain very limited. Adaptive thermogenesis promotes weight loss by dissipating energy in the form of heat, thereby representing a promising target to counteract obesity. Notably, the regulation of thermogenesis is tightly orchestrated by complex neuronal networks, especially those in the hypothalamus. Recent evidence highlights the importance of adenosine monophosphate-activated protein kinase (AMPK) within the ventromedial nucleus of the hypothalamus (VMH) in modulating thermogenesis. Various molecules, such as GLP-1, leptin, estradiol, and thyroid hormones, have been reported to act on the VMH to inhibit AMPK, which subsequently increases thermogenesis through the activation of the sympathetic nervous system (SNS). In this review, we summarize the critical role of AMPK within the VMH in the control of energy balance, focusing on its contribution to thermogenesis and the associated mechanisms.

show abstract

Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure

Cited by 11 publications

References 117 publications

Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial

Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

AMPK in the Ventromedial Nucleus of the Hypothalamus: A Key Regulator for Thermogenesis

Contact Info

Product

Resources

About